Earnings call transcript: ResMed Q3 2026 reports mixed results, stock steady

ResMed reported Q3 FY2026 EPS of $2.86, beating consensus by 1.78%, while revenue rose 11% year over year to $1.43 billion but missed expectations by 1.41%. Gross margin improved 290 bps to 62.8% and operating margin expanded to 36.7%, offsetting the revenue miss; the stock was little changed in after-hours trading. Management reaffirmed FY2026 gross margin guidance of 62%-63%, announced a $340 million acquisition of Noctrix Health, and continued capital returns with a $0.60 quarterly dividend plus $175 million in buybacks.

Analysis

RMD’s quarter reads stronger underneath the surface than the headline miss suggests: the real signal is that mix is still improving while the company is converting operating leverage into cash faster than revenue growth. That matters because in a premium medical-device franchise, sustained margin expansion usually tells you pricing power and channel discipline are intact even when top-line timing gets a little noisy. The market’s muted reaction looks right for one quarter, but not for the longer-term setup if gross margin can hold near the high-62% band while buybacks stay elevated.

The more important second-order effect is that RMD is increasingly behaving like a platform business, not a pure CPAP hardware vendor. The Noctrix tuck-in expands the addressable sleep-disorder funnel and, more importantly, gives management another reimbursement and prescriber workflow to monetize through the same DME/HME rails. If that integration works, the company can offset any slowing in core device growth with higher-frequency accessory and resupply economics — the kind of revenue that supports multiple expansion rather than compression.

The contrarian risk is that consensus may be underestimating how much of the current growth is being pulled forward by channel behavior and adjacent-demand effects from GLP-1s and home testing, rather than a clean step-up in underlying incidence. That creates a sequencing risk over the next 1-2 quarters: if referral conversion or payer economics wobble, investors could re-rate the name back toward a mature med-tech multiple. On the other hand, if the new CFO preserves capital-return discipline and Noctrix closes cleanly, the stock has room to de-risk upward over 3-6 months even without a big revenue beat.

Key Decisions for Investors

• Long RMD vs. short a med-tech basket or a slower-growth respiratory peer over 3-6 months: the setup is asymmetric because RMD has margin expansion, buybacks, and a new adjacently additive asset while valuation still reflects a near-term revenue stumble.
• Buy RMD on any 2-3% post-earnings weakness and target a 10-15% move over 6 months if gross margin holds above 62% and share repurchases continue at the current pace.
• Initiate a call spread in RMD for the next 4-6 months to express upside from margin durability and integration of Noctrix while limiting downside if the revenue miss becomes a pattern.
• Pair long RMD / short UNH or a payer-heavy managed-care name tactically for 1-2 quarters if you believe home-care utilization management remains manageable and the revenue mix shifts toward higher-value therapy/resupply.
• Avoid chasing the stock on the first print; wait for confirmation in the next quarter that the Noctrix integration is accretive to funnel economics before adding size.